Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O96019
UPID:
ACL6A_HUMAN
Alternative names:
53 kDa BRG1-associated factor A; Actin-related protein Baf53a; ArpNbeta; BRG1-associated factor 53A; INO80 complex subunit K
Alternative UPACC:
O96019; B3KMN1; D3DNR9; Q8TAE5; Q9BVS8; Q9H0W6
Background:
Actin-like protein 6A, also known as 53 kDa BRG1-associated factor A, plays a pivotal role in chromatin remodeling, influencing transcriptional activation and repression of genes. It is a crucial component of SWI/SNF complexes, altering DNA-nucleosome topology in an ATP-dependent manner. This protein is essential for the proliferation of neural progenitors and the transition to postmitotic neurons, indicating its significant role in neural development.
Therapeutic significance:
Understanding the role of Actin-like protein 6A could open doors to potential therapeutic strategies.